Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Twist Bioscience Corp (NQ: TWST ) 43.47 +0.68 (+1.58%) Streaming Delayed Price Updated: 10:35 AM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Twist Bioscience Corp < Previous 1 2 3 4 5 6 7 8 9 ... 14 15 Next > 4 Analysts Have This To Say About Twist Bioscience February 05, 2024 Via Benzinga Twist Bioscience Unveils Differentiated Ultra High-Throughput Library Preparation Solution at AGBT February 05, 2024 From Twist Bioscience Corporation Via Business Wire Why Is DNA Synthesis Company Twist Bioscience Stock Trading Higher Today? February 02, 2024 Twist Bioscience reported Q1 2024 earnings, beating revenue guidance and increasing FY24 guidance. Shares are up 7.16%. Via Benzinga Twist Bioscience Reports Fiscal First Quarter 2024 Financial Results February 02, 2024 From Twist Bioscience Corporation Via Business Wire Twist Bioscience Earnings Preview February 01, 2024 Via Benzinga Twist Bioscience Corp. (NASDAQ: TWST) Near the Top of Equities by Percentage Gain on 11/17 November 17, 2023 Via Investor Brand Network Twist Bioscience: Q4 Earnings Insights November 17, 2023 Via Benzinga Earnings Scheduled For February 2, 2024 February 02, 2024 Companies Reporting Before The Bell • W.W. Grainger (NYSE:GWW) is likely to report quarterly earnings at $8.05 per share on revenue of $4.04 billion. Via Benzinga Twist Bioscience Corp Daily Investment Opportunity January 25, 2024 Twist Bioscience is a public biotechnology company founded in 2013 and it’s based in South San Francisco. It manufactures synthetic DNA and DNA products for customers in a wide range of industries. Via Talk Markets Twist Bioscience Expands Express Genes Rapid Synthesis Service January 24, 2024 From Twist Bioscience Corporation Via Business Wire Goldman Sachs Upgrades Twist Bioscience, Says Express Genes Launch Will Drive Margin Expansion January 17, 2024 Goldman Sachs upgrades Twist Bioscience as Express Genes launch addresses SynBio division's gross margin issues. With 5-7 days gene delivery, TWST taps into a previously inaccessible market, enhancing... Via Benzinga Netflix To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Wednesday January 17, 2024 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga Twist Bioscience to Report Fiscal 2024 First Quarter Financial Results on Friday, February 2, 2024 January 16, 2024 From Twist Bioscience Corporation Via Business Wire Biotech Playbook: Small Caps Show Momentum Peaking During January 15, 2024 The momentum of selected stocks was strong up until early January was encouraging but we need less volatility in period ahead to conform a new bull market. Via Talk Markets Twist Bioscience Corporation Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) January 08, 2024 From Twist Bioscience Corporation Via Business Wire Twist Bioscience Appoints Adam Laponis as Chief Financial Officer January 05, 2024 From Twist Bioscience Corporation Via Business Wire 3 Genomics Stocks to Unlock the Future of Medicine December 19, 2023 Genomics stocks stand to surge in 2024 after the FDA approved the nation's first gene-editing therapeutic for clinical use. Via InvestorPlace Exposures Product Safety Twist Bioscience to Present at 42nd Annual J.P. Morgan Healthcare Conference December 18, 2023 From Twist Bioscience Corporation Via Business Wire Tuesday Talk: CPI Data And FOMC Meeting Hold Back Market Breakout December 12, 2023 While the market continues towards making new highs, it is falling short of making a breakout rally. Forthcoming CPI data and the upcoming FOMC meeting may be the catalyst for same. Via Talk Markets Biotech Is Coming Back, Can The Run Last? December 11, 2023 The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally. Via Talk Markets Five Best Performing Stocks Of The Top ETF Of November December 01, 2023 Most stocks in ARKK’s portfolio delivered strong returns in November. These five led the way. Via Talk Markets Topics ETFs Cramer Says No To This EV Maker, But Recommends This Major Automaker Stock: It 'Goes Up And Up' November 21, 2023 On CNBC’s "Mad Money Lightning Round," Jim Cramer said no to Lucid Group, Inc. Via Benzinga S&P 500 Edges Higher; Buckle Shares Surge After Q3 Earnings November 17, 2023 U.S. stocks traded slightly higher toward the end of trading, with the Nasdaq Composite gaining around 30 points on Friday. The Dow traded up 0.07% to 34,969.63 while the NASDAQ rose 0.21% to... Via Benzinga Topics Stocks Exposures US Equities Why Dolby Laboratories Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session November 17, 2023 Shares of Dolby Laboratories, Inc. (NYSE: DLB) fell during Friday’s session following weak guidance. Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session November 17, 2023 Via Benzinga Crude Oil Rises Over 3%; BJ's Wholesale Posts Weak Sales November 17, 2023 U.S. stocks traded mostly flat midway through trading on Friday. The Dow traded up 0.01% to 34,945.78 while the NASDAQ fell 0.03% to 14,109.53. The S&P 500 also rose, gaining, 0.05% to 4,510.71. Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities Ross Stores Reports Strong Earnings, Joins Buckle, Twist Bioscience And Other Big Stocks Moving Higher On Friday November 17, 2023 U.S. stocks traded mostly lower, with the Dow Jones falling over 20 points on Friday. Via Benzinga Topics Stocks Exposures US Equities DNA-Maker Twist Bioscience Catapults 21% As 'Solid' Outlook That Tops Its Peers November 17, 2023 The company expects sales to grow 16% to 18% in fiscal year 2024, which is already underway. Via Investor's Business Daily Why Synthetic DNA Company Twist Bioscience Shares Are Jumping Today November 17, 2023 Twist Bioscience Corp's (NASDAQ: TWST) Q4 sales increased 16.8% Y/Y to $66.9 million, Via Benzinga Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2023 Financial Results November 17, 2023 From Twist Bioscience Corporation Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 ... 14 15 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.